南模生物(688265) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥87,304,768.91, representing a year-on-year increase of 20.08%[5] - The net profit attributable to shareholders was a loss of ¥14,231,619.55, reflecting a decline of 202.22% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥18,252,406.90, down 302.52% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 87,304,768.91, an increase of 20.1% compared to CNY 72,706,319.65 in Q1 2022[21] - Net profit for Q1 2023 was a loss of CNY 14,231,619.55, compared to a profit of CNY 13,921,971.48 in Q1 2022[22] - The company reported a basic and diluted earnings per share of CNY -0.18 for Q1 2023, down from CNY 0.18 in Q1 2022[23] Expenses and Costs - Research and development expenses totaled ¥19,799,024.04, which is an increase of 73.02% compared to the previous year, accounting for 22.68% of operating revenue[6] - Total operating costs for Q1 2023 were CNY 101,776,392.04, up 65.5% from CNY 61,443,743.53 in Q1 2022[21] - Selling expenses rose to CNY 11,165,270.92 in Q1 2023, an increase of 49.5% from CNY 7,444,389.92 in Q1 2022[22] - The increase in management expenses was attributed to significant stock incentive costs and higher administrative staff salaries following the acquisition of Zhongyingjian[10] - The company experienced a significant increase in financial expenses, reporting CNY 652,480.86 in Q1 2023, compared to a gain of CNY -2,204,395.63 in Q1 2022[22] Cash Flow - The company reported a negative cash flow from operating activities of ¥33,872,953.18, which is not applicable for year-on-year comparison[5] - In Q1 2023, the company reported cash inflows from operating activities of ¥66,448,951.40, an increase of 31.9% compared to ¥50,345,556.32 in Q1 2022[24] - The cash outflows from operating activities totaled ¥100,321,904.58, up from ¥70,925,883.82 in the same period last year, resulting in a net cash flow from operating activities of -¥33,872,953.18[24] - The company achieved cash inflows from investment activities of ¥885,839,718.79, significantly higher than ¥527,414,596.75 in Q1 2022, with a net cash flow from investment activities of ¥31,629,037.84[25] - The company reported a net decrease in cash and cash equivalents of -¥8,743,172.73, compared to a much larger decrease of -¥1,309,037,546.86 in Q1 2022[25] - The ending balance of cash and cash equivalents was ¥358,699,458.77, compared to ¥256,106,060.25 in the same quarter last year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,053,201,079.68, a slight decrease of 0.02% from the end of the previous year[6] - The company's total liabilities as of Q1 2023 were CNY 296,880,628.50, compared to CNY 287,751,134.70 in the previous year[19] - The total equity attributable to shareholders was CNY 1,756,320,451.18, a slight decrease from CNY 1,765,926,830.82 in Q1 2022[19] - The company reported accounts receivable of RMB 138,422,312.72, an increase from RMB 92,636,686.51 year-over-year[17] - The company’s fixed assets are valued at RMB 118,640,906.99, a slight decrease from RMB 119,807,372.24[17] - The company’s non-current assets total RMB 814,749,046.94, up from RMB 793,021,392.26 year-over-year[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,229[12] - The largest shareholder, Shanghai Dish Consulting, holds 27,771,000 shares, representing 35.62% of total shares[12] Market and Expansion - The company is actively expanding its domestic and overseas markets, increasing its sales team to enhance market share[10] - The company expanded its production capacity from 100,000 cages to 140,000 cages, leading to increased costs in depreciation, materials, and labor[9] Other Information - The company has no reported new products or technologies, market expansions, or mergers during this reporting period[15] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[24] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[26]